Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) does reduce appetite — that is central to how it works. Most people notice they feel full sooner, think about food less often, and find large meals unappealing. This happens because semaglutide activates GLP-1 receptors that regulate hunger signals and slow how quickly food leaves the stomach. The shift can feel dramatic, especially in the first few weeks of treatment. As a prescription-only medicine, semaglutide must be prescribed following a clinical assessment, and a prescriber is best placed to help you manage appetite changes alongside your dose. This page explains what to expect, step by step, so you can tell the difference between a normal part of treatment and something worth flagging.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide mimics the gut hormone GLP-1, which is released naturally after eating. It acts on receptors in the brain's appetite-regulation centres, reducing the drive to eat, and it slows gastric emptying so food stays in the stomach longer. The result is that a small portion produces the same sensation of fullness that a large one did before. You can read a plain-English account of this mechanism on the NHS-informed page covering how Wegovy suppresses appetite if you want more detail on the biology.
Appetite suppression tends to be most pronounced at two points: early in treatment, when semaglutide is new to your system, and after each dose step upward. Most people starting on 0.25 mg notice relatively modest changes; those reaching 1.7 mg or 2.4 mg often find hunger feels almost absent on the harder days. That is not a malfunction. The NHS medicines page for semaglutide confirms that reduced appetite is an expected effect, not a side effect to report unless it becomes extreme.
If you are comparing this experience to a friend on a different medicine, bear in mind that tirzepatide works on two receptor pathways rather than one, our overview of semaglutide and appetite explains the distinction clearly.
Here is the practical challenge many people on Wegovy describe: hunger used to be the reminder to eat, and now that reminder has gone quiet. That can lead to skipping meals without intending to. Over weeks and months, consistently under-eating (particularly protein) can result in muscle loss alongside fat loss, which is not the outcome treatment is designed to produce.
The approach that works for most people is treating mealtimes as scheduled events rather than appetite-driven ones. Three structured meals a day, with priority given to protein (chicken, fish, eggs, legumes, dairy) and vegetables, tends to support both muscle retention and the sustained energy levels that help with activity. Our practical eating guide for Wegovy covers this in more detail, including how to build meals that stay satisfying in smaller portions.
Hydration matters more than many people expect. Reduced appetite often coincides with drinking less, which can make nausea and fatigue worse. Sipping water steadily across the day rather than in large amounts at once tends to sit more comfortably during treatment. If you find even small portions are causing nausea rather than just a lack of interest in food, that is a different issue worth raising with your prescriber.
It is one thing to feel less hungry. It is another to find you have eaten almost nothing for several days, are losing weight very rapidly, or feel lightheaded and weak. These are signals to contact your prescriber rather than waiting for your next scheduled check-in.
Rapid or severe appetite loss sometimes accompanies gastrointestinal side effects (nausea, vomiting, reflux) particularly after a dose increase. If that is the pattern, the prescriber may recommend a slower titration schedule or suggest strategies to make meals more tolerable. When appetite disappears almost completely on Wegovy is a question worth exploring separately; it covers when the effect goes beyond the expected range and what the clinical options are.
Also worth noting: if you are also taking an oral contraceptive, semaglutide can affect absorption of medicines taken by mouth, your prescriber should have discussed contraception choices with you, but the NHS England guidance on weight-management injections has a plain summary if you want to check. Separately, any severe or persistent stomach pain that travels to your back is an urgent symptom that needs same-day medical attention, not a wait-and-see.
Appetite changes are dose-related: they generally intensify as the dose increases and can settle as your body adapts. Some people choose to pause titration at a lower dose because the appetite suppression at that level is working well for them. That is a clinician-led decision, not something to do unilaterally by stretching pens or skipping injections.
If you are finding treatment difficult to manage nutritionally and wondering whether the cost or commitment is sustainable, it is worth understanding what a complete treatment package looks like, our guide to accessing Wegovy through a regulated UK pharmacy explains the clinical oversight that should accompany any prescription, including ongoing prescriber support.
If you are curious whether your experience lines up with what most people report, or whether a complete absence of appetite is different from ordinary suppression, this page addresses Wegovy and having no appetite at all specifically. Most people find that with structure and professional guidance, the appetite reduction becomes an asset rather than a difficulty.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.